Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

This study has been terminated.
Sponsor:
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00057343
First received: March 31, 2003
Last updated: September 8, 2006
Last verified: September 2006
  Purpose

The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.


Condition Intervention Phase
Non-Hodgkin's Lymphoma
Drug: Zevalin (ibritumomab tiuxetan)
Drug: Rituxan (rituximab)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL

Resource links provided by NLM:


Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Event-free survival

Secondary Outcome Measures:
  • overall response rate
  • complete response rate
  • unconfirmed complete response rate
  • partial response rate
  • duration of response
  • time to progression
  • time-to-next anticancer therapy
  • quality of life
  • overall survival
  • safety profile

Estimated Enrollment: 400
Study Start Date: March 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Summary of major inclusion and exclusion criteria. Other Safety criteria will need to be met.

Inclusion Criteria:

  • Histologically confirmed, relapsed or refractory CD20+ follicular B-cell NHL within 12 months of Study Day 1 (without clinical evidence of transformation). NHL must require treatment as determined by an increase in overall tumor size. The presence of B symptoms, and/or the presence of masses which are causing ongoing clinical symptoms.
  • Bidimensionally measurable disease meeting the minimum requirement of at least 1 lesion >/= 2.0 cm in a single dimension.
  • No lymphoma therapy for 3 weeks prior to Study Day 1.
  • Patients must be recovered from all toxicities associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy.
  • Signed IRB-approved informed consent.
  • Greater than 18 years of age.
  • Expected survival >/= 3 months.
  • WHO performance status of </= 2.
  • Acceptable hematologic status, liver function, renal function, and pulmonary function.
  • Female patients who are not pregnant or lactating.
  • Men and women of reproductive potential who are following accepted birth control methods.

Exclusion Criteria:

  • Patients with impaired bone marrow reserve, which may be indicated by prior myeloablative therapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue.
  • Prior radioimmunotherapy, including the Zevalin regimen.
  • Prior immunotherapy, including Rituxan therapy within 6 months of Study Day 1.
  • Rituxan-refractory (no response to most recent Rituxan-containing regimen, or TTP was < 6 months).
  • Presence of CNS lymphoma.
  • Patients with chronic lymphocytic leukemia (CLL).
  • Known history of HIV or AIDS.
  • Serious nonmalignant disease or infection
  • Major surgery, other than diagnostic surgery, within 4 weeks of Study Day 1.
  • Patients who received investigational product within 4 weeks of Study Day 1 or patients who may experience long-term toxicity from a previous investigational therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00057343

  Hide Study Locations
Locations
United States, Alabama
Research Site
Huntsville, Alabama, United States
United States, Arizona
Research Site
Scottsdale, Arizona, United States
United States, Arkansas
Research Site
Little Rock, Arkansas, United States
United States, California
Research Site
Bakersfield, California, United States
Research Site
Concord, California, United States
Research Site
Duarte, California, United States
Research Site
Loma Linda, California, United States
Research Site
Los Angeles, California, United States
Research Site
Mission Viejo, California, United States
Research Site
Newport Beach, California, United States
Research Site
Orange, California, United States
Research Site
Sacramento, California, United States
Biogen Idec Incorporated
San Diego, California, United States, 92121
Research Site
San Diego, California, United States
Research Site
Santa Barbara, California, United States
Research Site
Vallejo, California, United States
United States, Connecticut
Research Site
Farmington, Connecticut, United States
United States, Delaware
Research Site
Newark, Delaware, United States
United States, Florida
Research Site
Jacksonville, Florida, United States
Research Site
Lakeland, Florida, United States
United States, Idaho
Research Site
Boise, Idaho, United States
Research Site
Coeur D'Alene, Idaho, United States
United States, Illinois
Research Site
Aurora, Illinois, United States
Research Site
Chicago, Illinois, United States
Research Site
Evanston, Illinois, United States
Research Site
Harvey, Illinois, United States
Research Site
Maywood, Illinois, United States
Research Site
Urbana, Illinois, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
Research Site
Munster, Indiana, United States
United States, Kansas
Research Site
Kansas City, Kansas, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Flint, Michigan, United States
Research Site
Royal Oak, Michigan, United States
Research Site
St. Joseph, Michigan, United States
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States
Research Site
Rochester, Minnesota, United States
United States, Mississippi
Research Site
Jackson, Mississippi, United States
Research Site
Tupelo, Mississippi, United States
United States, Missouri
Research Site
Columbia, Missouri, United States
Research Site
Kansas City, Missouri, United States
Research Site
St. Louis, Missouri, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
Research Site
Farmington, New Mexico, United States
United States, New York
Research Site
Bronx, New York, United States
Research Site
Buffalo, New York, United States
Research Site
Manhasset, New York, United States
Research Site
New York, New York, United States
United States, North Dakota
Research Site
Bismark, North Dakota, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
Research Site
Toledo, Ohio, United States
United States, Oregon
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
Research Site
Greenville, South Carolina, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Lubbock, Texas, United States
Research Site
Temple, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Washington
Research Site
Bremerton, Washington, United States
United States, West Virginia
Research Site
Morgantown, West Virginia, United States
United States, Wisconsin
Research Site
Wausau, Wisconsin, United States
Sponsors and Collaborators
Biogen Idec
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00057343     History of Changes
Other Study ID Numbers: 106-10
Study First Received: March 31, 2003
Last Updated: September 8, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antibodies, Monoclonal
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on August 21, 2014